Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936663 · ClinicalTrials.gov registry record · Phase 4
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
A Phase 4 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT00936663: Clinical Trial Phase 4 study, sponsored by University of Nebraska.
NCT00936663 is a Phase 4 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936663, a Phase 4 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
Primary Outcome
Fasting blood glucose levels at 1 year
Interventions
- DRUG Placebo
- DRUG Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-07-06 |
| Est. Completion | 2010-06-01 |
| Phase | Phase 4 |
Why NCT00936663 stopped before completion
NCT00936663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00936663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00936663 about?
NCT00936663 is a clinical study titled "Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation". This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
What is the current status of trial NCT00936663?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2009-07-06. Estimated completion is 2010-06-01.
What interventions are being tested in trial NCT00936663?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT00936663?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00936663's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI